September 2025 has seen notable leadership appointments and financing activities within the biotech and med-tech sectors. CatalYm appointed Clinton Musil as CFO and chief business officer as it advances cancer therapies, while IQVIA named Michael Fedock as CFO to succeed Ron Bruehlman. Financing rounds include Salt AI raising funds for med-tech advancements and seven biopharmas including Clearmind and Jasper securing investments. These developments reflect ongoing realignments, strategic growth initiatives, and capital influxes shaping the industry’s trajectory.